REGORAFENIB E CHEMOEMBOLIZZAZIONE PER L’EPATOCARCINOMA NON RESECABILE. UNO STUDIO POSITIVO DI REAL WORLD EVIDENCE

Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study Yue Han et al. Abstract Background The benefits and tolerability of transarterial chemoembolization (TACE) combined with regorafenib as a second-line therapy has not been reported for unresectable hepatocellular carcinoma (HCC). This study aimed to explore the benefits and tolerability of TACE combined with…

OCCHIO AL MOLNUPIRAVIR PER OS COME ANTI COVID-19. QUALCHE RIFLESSIONE IN ATTESA DELLA APPROVAZIONE DA MEDICAL NEWS TODAY

Molnupiravir vs. COVID-19: Will the drug live up to the hype? Katharine Lang In the search for effective COVID-19 treatments, many drugs have failed to live up to their early promise. In a recent trial, seen as an important advance, the oral antiviral drug molnupiravir halved the risk of hospital admissions and deaths from COVID-19.…

COME INTERPRETARE UNA LINEA GUIDA ! DA JAMA

How to Interpret and Use a Clinical Practice Guideline or RecommendationUsers’ Guides to the Medical Literature Romina Brignardello-Petersen,et al. Abstract Importance  Clinicians may rely on recommendations from clinical practice guidelines for management of patients. Observations  A clinical practice guideline is a published statement that includes recommendations that are intended to optimize patient care. In the guideline development process,…

GESTIONE DELLE MALATTIE BENIGNE ANORETTALI: LE NUOVE LINEE GUIDA DALL’AMERICAN COLLEGE OF GASTROENTEROLOGY

ACG Clinical Guidelines: Management of Benign Anorectal Disorders Arnold Wald et al Abstract Benign anorectal disorders of structure and function are common in clinical practice. These guidelines summarize the preferred approach to the evaluation and management of defecation disorders, proctalgia syndromes, hemorrhoids, anal fissures, and fecal incontinence in adults and represent the official practice recommendations…

SCARICA IL MANUALE JBI PER LA SINTESI DELLE EVIDENZE “FREE” !

JBIMANUAL FOR EVIDENCE SYNTHESIS April 2021 JBI Manual for Evidence Synthesis Welcome to the JBI Manual for Evidence Synthesis JBI is an international evidence-based healthcare research organisation that works with 70+ Universities and Hospitals (known as the JBI Collaboration) around the world. The organisation focuses on improving health outcomes globally by producing and disseminating research…

UN NUOVO INIBITORE PER LA TERAPIA DELLA NASH DA GASTROENTEROLOGY: UN TRIAL

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial Rohit Loomba et al. Background & Aims Increased de novo lipogenesis creates excess intrahepatic fat and lipotoxins, propagating liver damage in nonalcoholic steatohepatitis. TVB-2640, a fatty acid synthase inhibitor, was designed to reduce excess liver fat and directly inhibit…